Odyssey Therapeutics (ODTX) Earnings Date
Does this company deliver against its own promises? Earnings are a check on the thesis, not a catalyst to chase.
0 of 1 scored quarter beat.
| Report | Est EPS | Act EPS | Surprise | Est rev | Act rev | Reaction |
|---|---|---|---|---|---|---|
| Nov 4, 20268-K, before open · 7:00 am ET | −1.07a Scored against the latest consensus we hold for this quarter, stored after the report; our record does not reach back to the night before it. | −1.10 | −2.5% | $0.00 | $0.00 | −9.6%release day |
| Aug 4, 20268-K, before open · 7:00 am ET | — | −1.74 | — | — | $0.00 | +10.1%release day |
| Jun 17, 20268-K, after close · 4:45 pm ET | — | −6.77 | — | — | $0.00 | +3.2%next session |
| Nov 4, 2025 E | — | −7.78 | — | — | $99,000.00 | —estimated date |
- a Scored against the latest consensus we hold for this quarter, stored after the report; our record does not reach back to the night before it.
None of the 4 quarters above is scored against a consensus we stored the night before its report; 1, marked a, is scored against the latest consensus we hold, stored after the report, which may have moved toward the result. 3 reported before we stored a consensus for them, so they are not scored.
E marks a report date we estimated from the fiscal period end, because we found no results release and no usable filing date for that quarter. Those rows show no reaction: a move measured from a day we guessed is not a reaction to the release, and we would rather leave it blank than publish it.
| Measure | Dec '26 | Mar '27 | FY26 | FY27 |
|---|---|---|---|---|
| No. of analysts | 4 | 3 | 5 | 6 |
| Avg estimate | −1.09 | −1.18 | −5.87 | −4.44 |
| Low estimate | −1.21 | −1.26 | −6.05 | −4.88 |
| High estimate | −1.01 | −1.10 | −5.77 | −3.55 |
| Year-ago EPS | — | −6.77 | — | −5.87E |
| Implied growth | — | — | — | — |
| Measure | Dec '26 | Mar '27 | FY26 | FY27 |
|---|---|---|---|---|
| No. of analysts | 0 | 0 | 7 | 7 |
| Avg estimate | $0.00 | $0.00 | $3.0M | $3.0M |
| Low estimate | $0.00 | $0.00 | $3.0M | $3.0M |
| High estimate | $0.00 | $0.00 | $3.0M | $3.0M |
| Year-ago revenue | — | $0.00 | — | $3.0ME |
| Implied growth | — | — | — | 0.0% |
| Snapshot age | Dec '26, period ending Dec 30, 2026 | Mar '27, period ending Mar 30, 2027 | FY26, period ending Dec 31, 2026 | FY27, period ending Dec 31, 2027 |
|---|---|---|---|---|
| Current estimate | −1.09 | −1.18 | −5.87 | −4.44 |
| 7 days ago | −1.09 | — | −5.87 | −4.44 |
| 30 days ago | — | — | — | — |
| 60 days ago | — | — | — | — |
| 90 days ago | — | — | — | — |
Estimate history accrues from our nightly snapshots. The 7/30/60/90-day rows fill in as tracking continues. Each column follows one fiscal period back through our snapshots; a dash means we had not recorded that period at that age. A rising bar makes a beat streak more meaningful; a falling one manufactures beats.
Dec '26 quarter consensus has held at −$1.09 across 7 tracked days since Nov 13, 2026. A bar that has not moved is an answer, not a gap: a beat against a flat bar is a real beat. Per-analyst up/down revision counts aren't in our data feed.
Common questions
What were Odyssey Therapeutics' latest quarterly earnings?
Odyssey Therapeutics reported diluted EPS of −1.10 and revenue of $0.00 on Nov 4, 2026.
How did Odyssey Therapeutics' stock move after its last earnings report?
Odyssey Therapeutics moved −9.6% in the session after its Nov 4, 2026 report.

